I think the incumbents have done an amazing job developing / marketing TAVR and penetrating a market that didn’t previously exist. I think Wayne’s comments are a little tongue in cheek and potentially misinterpreted (just IMO).
I think the main point to take away is that it is less about the companies and more about the limitations of their devices. The market is opening up for younger / lower risk patients but they haven’t been able to penetrate it to its full potential because their devices can’t do what they need to for younger patients (offer a lifetime solution).
DurAVR has the potential to offer this solution and therefore expand (massively) and then penetrate a market that is currently limited for others (although bigger than before).
So in my view it’s not about the companies abilities (Edwards and Medtronics are top shelf) it’s more about their device inadequacies and the optionality DurAVR will provide its future owners, Anteris or otherwise.
So I would be 100% happy for Medtronic or Edwards (or others like Abbott & Boston) to market DurAVR in the future for the right price / partnership.
Add to My Watchlist
What is My Watchlist?
